Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 265 articles:
HTML format
Text format



Single Articles


    April 2019
  1. BAJIS S, Grebely J, Cooper L, Smith J, et al
    Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112.
    PubMed     Text format     Abstract available


  2. INDOLFI G, Bailey H, Serranti D, Giaquinto C, et al
    Treatment and Monitoring of Children with Chronic Hepatitis C in the Pre-DAA Era: a European Survey of 38 Paediatric Specialists.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13111.
    PubMed     Text format     Abstract available


  3. KARNSAKUL W, Schwarz KB
    Management of HCV in Children in the Era of DAA's.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13113.
    PubMed     Text format     Abstract available


  4. POORDAD F, Sedghi S, Pockros PJ, Ravendhran N, et al
    Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13109.
    PubMed     Text format     Abstract available


  5. BACK D, Belperio P, Bondin M, Negro F, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis.
    J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110.
    PubMed     Text format     Abstract available


  6. TAMAKI N, Higuchi M, Kurosaki M, Kirino S, et al
    Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct acting antivirals.
    J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13103.
    PubMed     Text format     Abstract available


  7. CARABALLO CORTES K, Osuch S, Perlejewski K, Pawelczyk A, et al
    Expression of programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus (HCV) infection and in subjec
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13108.
    PubMed     Text format     Abstract available


  8. WEN B, Zhang J, Liu W, Tang P, et al
    HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses.
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13106.
    PubMed     Text format     Abstract available


    March 2019
  9. SIMMONS R, Ireland G, Ijaz S, Ramsay M, et al
    Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study.
    J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13096.
    PubMed     Text format     Abstract available


    February 2019
  10. WILSON EC, Turner C, Lin J, McFarland W, et al
    Hepatitis C seroprevalence and engagement in related care and treatment among transwomen.
    J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13089.
    PubMed     Text format     Abstract available


  11. PLATT L, Stengel CM, Nkurunziza M, Muhangi D, et al
    Assessing risk of HIV and hepatitis C among people who inject drugs in East Africa: findings from a rapid assessment.
    J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13088.
    PubMed     Text format     Abstract available


  12. TURKOVA A, Volynets GV, Crichton S, Skvortsova TA, et al
    Advanced liver disease in Russian children and adolescents with chronic hepatitis C.
    J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13093.
    PubMed     Text format     Abstract available


  13. DORE GJ
    HCV reinfection as a positive indication of high-risk population treatment access.
    J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13092.
    PubMed     Text format     Abstract available


  14. LATHAM NH, Pedrana A, Doyle JS, Howell J, et al
    Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13087.
    PubMed     Text format     Abstract available


  15. VANOPDORP JR, Ferrentino N, Strader DB, Lidofsky SD, et al
    Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct acting antiviral regimens.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13083.
    PubMed     Text format     Abstract available


  16. IDILMAN R, Demir M, Aladag M, Erol C, et al
    Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
    J Viral Hepat. 2019 Feb 11. doi: 10.1111/jvh.13075.
    PubMed     Text format     Abstract available


  17. FERENCI P, Bourgeois S, Buggisch P, Norris S, et al
    Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observation
    J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080.
    PubMed     Text format     Abstract available


  18. PALAZZO D, Biliotti E, Esvan R, Volpicelli L, et al
    Vitamin D deficiency and health-related quality of life in chronic hepatitis C.
    J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076.
    PubMed     Text format     Abstract available


  19. LAWITZ E, Poordad F, Anderson LJ, Vesay M, et al
    Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection.
    J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079.
    PubMed     Text format     Abstract available


    January 2019
  20. BLADOWSKA J, Pawlowski T, Fleischer-Stepniewska K, Knysz B, et al
    Interferon-free Therapy as the Cause of White Matter Tracts and Cerebral Perfusion Recovery in Patients with Chronic Hepatitis C.
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13069.
    PubMed     Text format     Abstract available


  21. JACK K, Thomson BJ, Irving WL
    Testing for hepatitis C virus infection in UK Prisons: what actually happens?
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13071.
    PubMed     Text format     Abstract available


  22. CHEN WC, Wei CK, Lee JC
    MicroRNA-let-7c suppresses hepatitis C virus replication by targeting Bach1 for induction of heme oxygenase-1 expression.
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13072.
    PubMed     Text format     Abstract available


  23. HARRIS RJ, Harris H, Mandal S, Ramsay M, et al
    Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.
    J Viral Hepat. 2019 Jan 21. doi: 10.1111/jvh.13063.
    PubMed     Text format     Abstract available


  24. RUANE P, Strasser SI, Gane EJ, Hyland RH, et al
    Sofosbuvir/Velpatasvir/Voxilaprevir for Patients with HCV Who Previously Received a Sofosbuvir/Velpatasvir-Containing Regimen: Results from a Retreatment Study.
    J Viral Hepat. 2019 Jan 21. doi: 10.1111/jvh.13067.
    PubMed     Text format     Abstract available


  25. GIROMETTI N, Devitt E, Phillips J, Nelson M, et al
    High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection.
    J Viral Hepat. 2019 Jan 19. doi: 10.1111/jvh.13066.
    PubMed     Text format     Abstract available


  26. XU R, Yu Y, Leitch ECM, Wang M, et al
    HCV genotype 6 prevalence, spontaneous clearance and diversity amongst elderly members of the Li ethnic minority in Baisha County, China.
    J Viral Hepat. 2019 Jan 10. doi: 10.1111/jvh.13062.
    PubMed     Text format     Abstract available


    December 2018
  27. RODRIGO C, Leung P, Lloyd AR, Bull RA, et al
    Genomic variability of within-host hepatitis C variants in acute infection.
    J Viral Hepat. 2018 Dec 22. doi: 10.1111/jvh.13051.
    PubMed     Text format     Abstract available


  28. RAMACHANDRAN J, Budd S, Slattery H, Muller K, et al
    Hepatitis C virus infection in Australian psychiatric in-patients: a multicenter study of seroprevalence, risk factors and treatment experience.
    J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13056.
    PubMed     Text format     Abstract available


  29. HENGST J, Klein AL, Lunemann S, Deterding K, et al
    Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection.
    J Viral Hepat. 2018 Dec 8. doi: 10.1111/jvh.13050.
    PubMed     Text format     Abstract available


  30. POURMARZI D, Hall L, Hepworth J, Smirnov A, et al
    Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of Hepatitis C Virus infection: a mixed method systematic review.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13045.
    PubMed     Text format     Abstract available


  31. LEE SS, Kim CY, Kim BR, Cha RR, et al
    Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13047.
    PubMed     Text format     Abstract available


  32. RAUWOLF K, Herbruggen H, Zollner S, Thorer H, et al
    Durable control of Hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic hematopoietic stem cell transplantation.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13046.
    PubMed     Text format     Abstract available


    November 2018
  33. HOLMES JA, Carlton-Smith C, Kim AY, Dumas EO, et al
    Dynamic Changes in Innate Immune Responses During Direct Acting Antiviral Therapy for HCV Infection.
    J Viral Hepat. 2018 Nov 19. doi: 10.1111/jvh.13041.
    PubMed     Text format     Abstract available


  34. KAPILA N, Flocco G, Al Khalloufi K, Zervos XB, et al
    Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting anti-viral therapy without ribavirin.
    J Viral Hepat. 2018 Nov 18. doi: 10.1111/jvh.13042.
    PubMed     Text format     Abstract available


  35. BUTT ZA, Mak S, Gesink D, Gilbert M, et al
    Applying core theory and spatial analysis to identify Hepatitis C Virus infection 'core areas' in British Columbia, Canada.
    J Viral Hepat. 2018 Nov 17. doi: 10.1111/jvh.13043.
    PubMed     Text format     Abstract available


  36. SCHULKIND J, Stephens B, Ahmad F, Johnston L, et al
    High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.
    J Viral Hepat. 2018 Nov 13. doi: 10.1111/jvh.13035.
    PubMed     Text format     Abstract available


  37. FLAMM S, Mutimer D, Asatryan A, Wang S, et al
    Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis.
    J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038.
    PubMed     Text format     Abstract available


  38. SERFATY L, Jacobson I, Rockstroh J, Altice FL, et al
    The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis.
    J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13037.
    PubMed     Text format     Abstract available


  39. YOUNG K, Liu B, Bhuket T, Gish RG, et al
    Improved Liver Transplant Waitlist Mortality and Lower Risk of Disease Progression Among Chronic Hepatitis C Patients Awaiting Liver Transplantation After the Introduction of Direct Acting Antiviral Therapies in the United States.
    J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13039.
    PubMed     Text format     Abstract available


  40. ORR C, Aartun J, Masur H, Kottilil S, et al
    Characterization of Changes in Intrahepatic Immune Cell Populations During HCV Treatment with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2018 Nov 1. doi: 10.1111/jvh.13034.
    PubMed     Text format     Abstract available


  41. YOUNOSSI Z, Papatheodoridis G, Cacoub P, Negro F, et al
    The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease.
    J Viral Hepat. 2018;25 Suppl 3:6-14.
    PubMed     Text format     Abstract available


    October 2018
  42. WU DB, Jiang W, Wang YH, Chen B, et al
    Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in southwest China: real-world experience of a retrospective study.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13033.
    PubMed     Text format     Abstract available


  43. ABDEL GHAFFAR TY, Naghi SE, Gawad MA, Helmy S, et al
    Safety and Efficacy of Combined Sofosbuvir/Daclatasvir Treatment of Children and Adolescents with Chronic Hepatitis C Genotype 4.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13032.
    PubMed     Text format     Abstract available


  44. HUANG J, Yin P, Zhang L
    COPII cargo claudin-12 promotes hepatitis C virus entry.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13026.
    PubMed     Text format     Abstract available


  45. SARKAR M, Lai JC, Sawinski D, Zeigler TE, et al
    Sex Hormone Levels by Presence and Severity of Cirrhosis in Women With Chronic Hepatitis C Virus (HCV) Infection.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13027.
    PubMed     Text format     Abstract available


  46. WANG M, Ping Y, Li Z, Li J, et al
    Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signaling.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13024.
    PubMed     Text format     Abstract available


  47. VAZIRI A, Gimson A, Agarwal K, Aldersley M, et al
    Liver transplant listing for hepatitis C associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct acting antiviral therapy.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13022.
    PubMed     Text format     Abstract available


  48. GIRARDIN F, Hearmon N, Negro F, Eddowes L, et al
    Increasing Hepatitis C Virus Screening in People Who Inject Drugs in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing: a Cost-Effectiveness Analysis.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13023.
    PubMed     Text format     Abstract available


  49. KNOP V, Hofmann WP, Buggisch P, Klinker H, et al
    Estimation of liver fibrosis by non-commercial serum markers in comparison to transient elastography in patients with chronic hepatitis C virus infection receiving direct acting antiviral treatment.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13021.
    PubMed     Text format     Abstract available


  50. MOREY S, Hamoodi A, Jones D, Young T, et al
    Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017.
    PubMed     Text format     Abstract available


  51. GOUTZAMANIS S, Doyle J, Higgs P, Hellard M, et al
    Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13020.
    PubMed     Text format     Abstract available


  52. MCLEOD A, Weir A, Hutchinson SJ, Goldberg DJ, et al
    Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness-raising campaign.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13016.
    PubMed     Text format     Abstract available


    September 2018
  53. KWON JA, Dore GJ, Grebely J, Hajarizadeh B, et al
    Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modeling study.
    J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13013.
    PubMed     Text format     Abstract available


  54. HERNANDEZ-CONDE M, Fernandez I, Perello C, Gallego A, et al
    Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort.
    J Viral Hepat. 2018 Sep 28. doi: 10.1111/jvh.13008.
    PubMed     Text format     Abstract available


  55. MALAGUTI A, Sani F, Stephens BP, Ahmad F, et al
    Change in injecting behaviour among people treated for hepatitis C virus: the role of intimate partnerships.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13009.
    PubMed     Text format     Abstract available


  56. XIA Y, Pan W, Ke X, Skibbe K, et al
    Differential escape of HCV from CD8(+) T cell selection pressure between China and Germany depends on the presenting HLA class I molecule.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13011.
    PubMed     Text format     Abstract available


  57. MACIAS J, Tellez F, Rivero-Juarez A, Palacios R, et al
    Early emergence of opportunistic infections after starting direct acting antiviral drugs in HIV/HCV coinfected patients.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13003.
    PubMed     Text format     Abstract available


  58. IWAMOTO M, Calzia A, Dublineau A, Rouet F, et al
    Field evaluation of GeneXpert((R)) (Cepheid) HCV performance for RNA quantification in a Genotype 1 and 6 predominant patient population in Cambodia.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13002.
    PubMed     Text format     Abstract available


  59. RODGERS MA, Holzmayer V, Vallari A, Olivo A, et al
    Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12996.
    PubMed     Text format     Abstract available


  60. DUONG MC, McLaws ML
    Screening hemodialysis patients for hepatitis C in Vietnam: the inconsistency between common hepatitis C virus serological and virological tests.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12994.
    PubMed     Text format     Abstract available


  61. VROLING H, Oordt-Speets AM, Madeddu G, Babudieri S, et al
    A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12998.
    PubMed     Text format     Abstract available


    August 2018
  62. LAFFERTY L, Rance J, Grebely J, Lloyd AR, et al
    Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12987.
    PubMed     Text format     Abstract available


  63. PERPINAN E, Caro-Perez N, Garcia-Gonzalez N, Gregori J, et al
    Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12986.
    PubMed     Text format     Abstract available


  64. SAEED S, Moodie EE, Strumpf E, Gill J, et al
    Real-World Impact of Direct Acting Antiviral Therapy on Health-Related Quality of Life in HIV/Hepatitis C Co-Infected Individuals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12985.
    PubMed     Text format     Abstract available


  65. JONES H, Patel P, Sears D
    Electronic Reminders Increase Hepatitis C Screening, referral, treatment and cure.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12988.
    PubMed     Text format     Abstract available


  66. MACIAS J, Granados R, Tellez F, Merino D, et al
    Similar recovery of liver function after response to all oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12990.
    PubMed     Text format     Abstract available


  67. LIM SG, Phyo WW, Shah SR, Win KM, et al
    Findings from a large asian chronic hepatitis c real life study.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12989.
    PubMed     Text format     Abstract available


  68. DIRKS M, Haag K, Pflugrad H, Tryc AB, et al
    Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.
    J Viral Hepat. 2018 Aug 18. doi: 10.1111/jvh.12979.
    PubMed     Text format     Abstract available


  69. SINGH A, Kumari S, Kumar P, De A, et al
    Sofosbuvir with NS5A Inhibitors in Hepatitis C Virus (HCV) Infection with Severe Renal Insufficiency.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12983.
    PubMed     Text format     Abstract available


  70. MASETTI C, Lionetti R, Lupo M, Siciliano M, et al
    Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12982.
    PubMed     Text format     Abstract available


    July 2018
  71. SCOTT N, Sacks-Davis R, Pedrana A, Doyle J, et al
    Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12975.
    PubMed     Text format     Abstract available


  72. DARVISHIAN M, Janjua NZ, Chong M, Cook D, et al
    Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12977.
    PubMed     Text format     Abstract available


  73. SUGIURA A, Joshita S, Umemura T, Yamazaki T, et al
    Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.
    J Viral Hepat. 2018 Jul 25. doi: 10.1111/jvh.12973.
    PubMed     Text format     Abstract available


  74. KABERG M, Naver G, Hammarberg A, Weiland O, et al
    Incidence and spontaneous clearance of hepatitis C (HCV) in PWID at the Stockholm Needle Exchange - importance for HCV elimination.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12969.
    PubMed     Text format     Abstract available


  75. HAYASHI K, Ishigami M, Ishizu Y, Kuzuya T, et al
    Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12967.
    PubMed     Text format     Abstract available


  76. YOUNOSSI ZM, Stepanova M, Henry L, Han KH, et al
    Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jul 4. doi: 10.1111/jvh.12965.
    PubMed     Text format     Abstract available


  77. MOHAMED Z, Rwegasha J, Kim JU, Shimakawa Y, et al
    The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania.
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12966.
    PubMed     Text format     Abstract available


    June 2018
  78. HSIEH YH, Patel AV, Loevinsohn GS, Thomas DL, et al
    Emergency Departments at the Crossroads of Intersecting Epidemics (HIV, HCV, Injection Drug Use, and Opioid Overdose) - Estimating HCV Incidence in an Urban Emergency Department Population.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12948.
    PubMed     Text format     Abstract available


  79. HARIDY J, Wigg A, Muller K, Ramachandran J, et al
    Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12943.
    PubMed     Text format     Abstract available


  80. DINESHA TR, Boobalan J, Sivamalar S, Subashini D, et al
    Occult HBV infection in HIV-infected adults and evaluation of pooled NAT for HBV.
    J Viral Hepat. 2018;25:718-723.
    PubMed     Text format     Abstract available


    May 2018
  81. LIU Z, Yang Q, Shi O, Ye W, et al
    The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population based study.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12938.
    PubMed     Text format     Abstract available


  82. KRAMER JR, Puenpatom A, Erickson K, Cao Y, et al
    Real-World Effectiveness of Elbasvir/Grazoprevir in HCV-Infected Patients in the US Veterans Affairs Healthcare System.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12937.
    PubMed     Text format     Abstract available


  83. AISYAH DN, Shallcross L, Hayward A, Aldridge RW, et al
    Hepatitis C among Vulnerable Populations: A Seroprevalence Study of Homeless, People Who Inject Drugs and Prisoners in London.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12936.
    PubMed     Text format     Abstract available


  84. MARCO A, Roget M, Cervantes M, Forne M, et al
    Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and non-inmates.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12940.
    PubMed     Text format     Abstract available


  85. JEONG Y, Jin B, Lee HW, Park HJ, et al
    Evolution and Persistence of the Resistance-Associated Substitutions of Hepatitis C Virus after Direct-Acting Antiviral Treatment Failures.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12932.
    PubMed     Text format     Abstract available


  86. CARDOSO AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, et al
    Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with Controlled Attenuation Parameter (CAP).
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12930.
    PubMed     Text format     Abstract available


  87. DEMING R, Ford MM, Moore MS, Lim S, et al
    Evaluation of a hepatitis C clinical care coordination program's effect on treatment initiation and cure: A surveillance-based propensity score matching approach.
    J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929.
    PubMed     Text format     Abstract available


    April 2018
  88. MARTINELLO M, Bhagani S, Gane E, Orkin C, et al
    Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917.
    PubMed     Text format     Abstract available


  89. WADE AJ, McCormack A, Roder C, McDonald K, et al
    Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910.
    PubMed     Text format     Abstract available


  90. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919.
    PubMed     Text format     Abstract available


  91. ANGELIDAKIS G, Hwang JP, Dandachi D, Economides MP, et al
    Universal screening for hepatitis C: a needed approach in patients with hematologic malignancies.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12913.
    PubMed     Text format     Abstract available


  92. YOO SH, Kwon JH, Nam SW, Kim HY, et al
    Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12918.
    PubMed     Text format     Abstract available


  93. WISLOFF T, White R, Dalgard O, Amundsen EJ, et al
    Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12904.
    PubMed     Text format     Abstract available


  94. SCHNELL G, Tripathi R, Beyer J, Reisch T, et al
    Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4-Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12906.
    PubMed     Text format     Abstract available


  95. MOORE MS, Bocour A, Winters A
    Dialysis Facility Screening and Testing Practices in the Era of Improved Hepatitis C Treatment.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12907.
    PubMed     Text format     Abstract available


    March 2018
  96. HOSHINO K, Sugiyama M, Date T, Maruwaka S, et al
    Phylogenetic and phylodynamic analysis of hepatitis C virus subtype 1a in Okinawa, Japan.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12898.
    PubMed     Text format     Abstract available


  97. WANG H, Swann R, Thomas E, Innes HA, et al
    Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897.
    PubMed     Text format     Abstract available


  98. BOYD SD, Harrington P, Komatsu TE, Naeger LK, et al
    HCV Genotype 4, 5, and 6: Distribution of Viral Subtypes and Sustained Virologic Response Rates in Clinical Trials of Approved Direct-acting Antiviral Regimens.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12896.
    PubMed     Text format     Abstract available


  99. NJOUOM R, Siffert I, Texier G, Lachenal G, et al
    The burden of Hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12894.
    PubMed     Text format     Abstract available


  100. GOOSSENS N, de Vito C, Mangia A, Clement S, et al
    Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12891.
    PubMed     Text format     Abstract available


  101. FEDELI U
    Increasing mortality associated with the more recent epidemic wave of Hepatitis C virus infection in Northern Italy.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12893.
    PubMed     Text format     Abstract available


  102. PAPATHEODORIDIS GV, Hatzakis A, Cholongitas E, Baptista-Leite R, et al
    Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    J Viral Hepat. 2018;25 Suppl 1:6-17.
    PubMed     Text format     Abstract available


    February 2018
  103. MACLEAN CD, Berger C, Cangiano ML, Ziegelman D, et al
    Impact of Electronic Reminder Systems on Hepatitis C Screening in Primary Care.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12885.
    PubMed     Text format     Abstract available


  104. CHEN JY, Ren Y, Yan P, Belina ME, et al
    Tricyclic Antidepressant Use and the Risk of Fibrosis Progression in Hepatitis C-Infected Persons: Results from ERCHIVES.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12884.
    PubMed     Text format     Abstract available


  105. LI J, Zhang T, Gordon SC, Rupp LB, et al
    Impact of sustained virological response on risk of type 2 diabetes among hepatitis C patients in the US.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12887.
    PubMed     Text format     Abstract available


  106. YOUNOSSI ZM, Tanaka A, Eguchi Y, Henry L, et al
    Treatment of Hepatitis C Virus Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma and Decompensated Cirrhosis in Japan.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12886.
    PubMed     Text format     Abstract available


  107. DUARTE G, Williams CJ, Vasconcelos P, Nogueira P, et al
    Capacity to report on mortality attributable to chronic Hepatitis B and C infections by Member States: an exercise to monitor progress toward viral hepatitis elimination.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12882.
    PubMed     Text format     Abstract available


  108. OLVEIRA A, Dominguez L, Troya J, Arias A, et al
    Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12883.
    PubMed     Text format     Abstract available


  109. CACOUB P, Buggisch P, Carrion JA, S Cooke G, et al
    Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Infection in Europe.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12881.
    PubMed     Text format     Abstract available


  110. CORTESI PA, Belli LS, Facchetti R, Mazzarelli C, et al
    The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877.
    PubMed     Text format     Abstract available


  111. HEDENSTIERNA M, Nangarhari A, El-Sabini A, Weiland O, et al
    Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virologic response in chronic hepatitis C.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12879.
    PubMed     Text format     Abstract available


  112. PREDA CM, Popescu CP, Baicus C, Constantinescu I, et al
    Risk of HBV reactivation in HBV+HCV coinfected patients with compensated liver cirrhosis treated with Ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12872.
    PubMed     Text format     Abstract available


  113. LUXENBURGER H, Grass F, Baermann J, Boettler T, et al
    Differential virus-specific CD8(+) T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12874.
    PubMed     Text format     Abstract available


  114. WALKER AJ, Peacock CJ, Pedergnana V, Irving WL, et al
    Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12871.
    PubMed     Text format     Abstract available


    January 2018
  115. ALVAREZ-OSSORIO MJ, Sarmento E Castro R, Granados R, Macias J, et al
    Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12867.
    PubMed     Text format     Abstract available


  116. GUPTA S, Rout G, Patel AH, Mahanta M, et al
    Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12870.
    PubMed     Text format     Abstract available


  117. HARRIS M, Bonnington O, Harrison G, Hickman M, et al
    Understanding hepatitis C intervention success: Qualitative findings from the HepCATT study.
    J Viral Hepat. 2018 Jan 25. doi: 10.1111/jvh.12869.
    PubMed     Text format     Abstract available


  118. AYOUB HH, Al Kanaani Z, Abu-Raddad LJ
    Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12864.
    PubMed     Text format     Abstract available


  119. AISYAH DN, Shallcross L, Hully AJ, O'Brien A, et al
    Assessing Hepatitis C Spontaneous Clearance and Understanding Associated Factors: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12866.
    PubMed     Text format     Abstract available


  120. COLOMBO M, Boccaccio V
    Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12862.
    PubMed     Text format     Abstract available


  121. FLISIAK R, Zarebska-Michaluk D, Janczewska E, Staniaszek A, et al
    Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12861.
    PubMed     Text format     Abstract available


  122. YOUNG K, Haq K, MacLean S, Dudani R, et al
    Development of a recombinant murine tumor model using hepatoma cells expressing hepatitis C virus (HCV) non-structural antigens.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12856.
    PubMed     Text format     Abstract available


  123. FALADE-NWULIA O, Sulkowski MS, Merkow A, Latkin C, et al
    Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12859.
    PubMed     Text format     Abstract available


  124. LAU KC, Osiowy C, Giles E, Lusina B, et al
    Deep Sequencing Shows Low Level Oncogenic Hepatitis B Virus Variants Persisting Post-Liver Transplant Despite Potent Anti-HBV Prophylaxis.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12860.
    PubMed     Text format     Abstract available


  125. SCHUTZ A, Moser S, Schwanke C, Schubert R, et al
    Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk for non-adherence to direct-acting antivirals.
    J Viral Hepat. 2018 Jan 5. doi: 10.1111/jvh.12857.
    PubMed     Text format     Abstract available


    December 2017
  126. EL KASSAS M, Funk AL, Salaheldin M, Shimakawa Y, et al
    Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12854.
    PubMed     Text format     Abstract available


  127. SULKOWSKI MS, Feld JJ, Lawitz E, Felizarta F, et al
    Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12853.
    PubMed     Text format     Abstract available


  128. HAJARIZADEH B, Grebely J, Matthews GV, Martinello M, et al
    Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12852.
    PubMed     Text format     Abstract available


  129. KOZUKA R, Hai H, Motoyama H, Hagihara A, et al
    The Presence of Multiple NS5A RASs is Associated with the Outcome of Sofosbuvir and Ledipasvir Therapy in NS5A Inhibitor-Naive Patients with Chronic HCV Genotype 1b Infection in a Real-World Cohort.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12850.
    PubMed     Text format     Abstract available


  130. MCNAUGHTON AL, Sreenu VB, Wilkie G, Gunson R, et al
    Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12849.
    PubMed     Text format     Abstract available


  131. GUBAY F, Staunton R, Metzig C, Abubakar I, et al
    Assessing uncertainty in the burden of Hepatitis C Virus: comparison of estimated disease burden and treatment costs in the UK.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12847.
    PubMed     Text format     Abstract available


  132. SIMMONS R, Ireland G, Irving W, Hickman M, et al
    Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12844.
    PubMed     Text format     Abstract available


  133. RODRIGUEZ DE SANTIAGO E, Velazquez Kennedy K, Garcia Gonzalez M, Gea Rodriguez F, et al
    HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12843.
    PubMed     Text format     Abstract available


  134. READ SA, Parnell G, Booth D, Douglas MW, et al
    The Antiviral Role of Zinc and Metallothioneins in Hepatitis C Infection.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12845.
    PubMed     Text format     Abstract available


  135. ERMAN A, Sathya A, Nam A, Bielecki JM, et al
    Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12846.
    PubMed     Text format     Abstract available


    November 2017
  136. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12837.
    PubMed     Text format     Abstract available


  137. TAMORI A, Abiru S, Enomoto H, Kioka K, et al
    Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12840.
    PubMed     Text format     Abstract available


  138. CARLTON-SMITH C, Holmes JA, Naggie S, Lidofsky A, et al
    IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
    J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12836.
    PubMed     Text format     Abstract available


  139. YOUNOSSI ZM, Stepanova M, Schwarz KB, Wirth S, et al
    Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12830.
    PubMed     Text format     Abstract available


  140. TANAKA J, Akita T, Ohisa M, Sakamune K, et al
    Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12828.
    PubMed     Text format     Abstract available


  141. KEISER O, Giudici F, Mullhaupt B, Junker C, et al
    Trends in hepatitis C-related mortality in Switzerland.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12803.
    PubMed     Text format     Abstract available


  142. BROWN A, Hezode C, Zuckerman E, Foster GR, et al
    Efficacy and safety of 12 weeks of elbasvir +/- grazoprevir +/- ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801.
    PubMed     Text format     Abstract available


  143. DUCHESNE L, Lacombe K
    Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings.
    J Viral Hepat. 2017 Nov 13. doi: 10.1111/jvh.12827.
    PubMed     Text format     Abstract available


  144. BHARDWAJ N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, et al
    Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12825.
    PubMed     Text format     Abstract available


  145. SALMON-CERON D, Mondelli MU, Maticic M, Arends JE, et al
    The success of HCV cure: every rose has its thorn.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12823.
    PubMed     Text format     Abstract available


  146. HIKITA H, Sato M, Sato M, Soroida Y, et al
    Disappearance of Perihepatic Lymph Node Enlargement after hepatitis C viral eradication with direct acting antivirals.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12819.
    PubMed     Text format     Abstract available


  147. DE ARAUJO NETO JM, Coelho HSM, Chindamo MC, da Motta Rezende GF, et al
    Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12812.
    PubMed     Text format     Abstract available


  148. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Elastogram quality assessment score in Vibration Controlled Transient Elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12822.
    PubMed     Text format     Abstract available


    October 2017
  149. CAMPANA B, Calabrese D, Matter MS, Terracciano LM, et al
    In vivo analysis at the cellular level reveals similar steatosis induction in both HCV genotype 1 and 3 infections.
    J Viral Hepat. 2017 Oct 31. doi: 10.1111/jvh.12816.
    PubMed     Text format     Abstract available


  150. MARCELLIN F, Morlat P, Wittkop L, Salmon-Ceron D, et al
    Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12811.
    PubMed     Text format     Abstract available


  151. CHOI HY, Kim Y, Cho H, Kim BH, et al
    Risk of diabetes in viral hepatitis B or C patients compared to that in non-infected individuals in Korea, 2002-2013: A population-based cohort study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12815.
    PubMed     Text format     Abstract available


  152. OW MM, Hegazy D, Warshow UM, Cramp ME, et al
    Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood.
    J Viral Hepat. 2017 Oct 24. doi: 10.1111/jvh.12810.
    PubMed     Text format     Abstract available


  153. SALUDES V, Folch C, Morales-Carmona A, Ferrer L, et al
    Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12809.
    PubMed     Text format     Abstract available


  154. YOUNOSSI ZM, Chan HLY, Dan YY, Lee MH, et al
    Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Genotype 1 Chronic Hepatitis C Patients in Asia.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12808.
    PubMed     Text format     Abstract available


  155. WONG NS, Lee CK, Ng SC, Wong HK, et al
    Prevalence of hepatitis C infection and its associated factors in healthy adults without identifiable route of transmission.
    J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12804.
    PubMed     Text format     Abstract available


  156. CAMUS G, Han B, Asselah T, Hsieh D, et al
    Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12795.
    PubMed     Text format     Abstract available


  157. TANG L, Parker A, Flores Y, Dellario M, et al
    Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12796.
    PubMed     Text format     Abstract available


  158. NORDMANN S, Vilotitch A, Roux P, Esterle L, et al
    Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12797.
    PubMed     Text format     Abstract available


  159. WEIL C, Mehta D, Koren G, Pinsky B, et al
    Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12800.
    PubMed     Text format     Abstract available


  160. CHEN DS, Hamoudi W, Mustapha B, Layden J, et al
    Strategies to manage hepatitis C virus infection disease burden-Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:44-63.
    PubMed     Text format     Abstract available


  161. MAAROUFI A, Vince A, Himatt SM, Mohamed R, et al
    Historical epidemiology of hepatitis C virus in select countries-volume 4.
    J Viral Hepat. 2017;24 Suppl 2:8-24.
    PubMed     Text format     Abstract available


  162. DORE GJ, Hatzakis A, Negro F, Waked I, et al
    Estimating HCV disease burden-volume 4 (editorial).
    J Viral Hepat. 2017;24 Suppl 2:4-7.
    PubMed     Text format     Abstract available


  163. CHAN HLY, Chen CJ, Omede O, Al Qamish J, et al
    The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:25-43.
    PubMed     Text format     Abstract available


    August 2017
  164. SERPER M, Forde KA, Kaplan DE
    Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort.
    J Viral Hepat. 2017 Aug 28. doi: 10.1111/jvh.12784.
    PubMed     Text format     Abstract available


  165. SHAFRAN SD, Shaw D, Charafeddine M, Agarwal K, et al
    Efficacy and Safety Results of Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/ritonavir and Sofosbuvir with or without Ribavirin (QUARTZ II-III).
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12782.
    PubMed     Text format     Abstract available


  166. KITRINOS KM, Corsa AC, Worth A, Hedskog C, et al
    Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12783.
    PubMed     Text format     Abstract available


  167. KRAMER JR, El-Serag HB, Taylor TJ, White DL, et al
    Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
    J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728.
    PubMed     Text format     Abstract available


  168. BARONE M, Iannone A, Shahini E, Ippolito AM, et al
    A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study.
    J Viral Hepat. 2017 Aug 8. doi: 10.1111/jvh.12765.
    PubMed     Text format     Abstract available


  169. MERCHANTE N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, et al
    Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12769.
    PubMed     Text format     Abstract available


  170. VON FELDEN J, Scheurich C, Yamamura J, Brainard DM, et al
    Successful treatment of chronic hepatitis C with ground ledipasvir / sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12768.
    PubMed     Text format     Abstract available


  171. FOURNIER C, Hoffmann TW, Morel V, Descamps V, et al
    Claudin-1, miR-122 and Apolipoprotein E transduction improves the permissivity of SNU-182, SNU-398 and SNU-449 Hepatoma cells to Hepatitis C Virus.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12767.
    PubMed     Text format     Abstract available


    July 2017
  172. HALLAGER S, Ladelund S, Kjaer MS, Madsen LG, et al
    Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study.
    J Viral Hepat. 2017 Jul 27. doi: 10.1111/jvh.12764.
    PubMed     Text format     Abstract available


  173. JACKA B, Bray B, Applegate TL, Marshall BD, et al
    Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758.
    PubMed     Text format     Abstract available


  174. SOLOMON SS, Sulkowski MS, Amrose P, Srikrishnan AK, et al
    Directly Observed Therapy of Sofosbuvir/Ribavirin +/- Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12761.
    PubMed     Text format     Abstract available


  175. CALVARUSO V, Ferraro D, Licata A, Bavetta MG, et al
    HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct acting antivirals.
    J Viral Hepat. 2017 Jul 13. doi: 10.1111/jvh.12754.
    PubMed     Text format     Abstract available


  176. GARDNER SD, Kim J, Baptiste-Brown S, Lopez V, et al
    GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naive chronic hepatitis C subjects.
    J Viral Hepat. 2017 Jul 10. doi: 10.1111/jvh.12753.
    PubMed     Text format     Abstract available


  177. SALAZAR-VIZCAYA L, Kouyos RD, Fehr J, Braun D, et al
    On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12752.
    PubMed     Text format     Abstract available


    June 2017
  178. BENOVA L, Awad SF, Abu-Raddad LJ
    Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts.
    J Viral Hepat. 2017 Jun 29. doi: 10.1111/jvh.12748.
    PubMed     Text format     Abstract available


  179. LI Y, Li Y, Zhang L, Li W, et al
    Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies.
    J Viral Hepat. 2017 Jun 28. doi: 10.1111/jvh.12742.
    PubMed     Text format     Abstract available


  180. TENG W, Hsieh YC, Lui KW, Chen WT, et al
    Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12745.
    PubMed     Text format     Abstract available


  181. SCHIAVINATO A, Zanetto A, Pantano G, Tosato F, et al
    Polyclonal and monoclonal B-lymphocytes response in HCV patients treated with direct-acting antiviral agents.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12746.
    PubMed     Text format     Abstract available


  182. DIRKS M, Pflugrad H, Weissenborn K
    Response to letter to the editor: Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12740.
    PubMed     Text format     Abstract available


  183. DE LA TORRE AN, Castaneda I, Ahmad M, Ekholy N, et al
    Audio Computer Assisted Survey Interview and Patient Navigation to Increase Chronic Viral Hepatitis Diagnosis and Linkage to Care in Urban Health Clinics.
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12744.
    PubMed     Text format     Abstract available


  184. GADE A
    Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12743.
    PubMed     Text format     Abstract available


  185. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12737.
    PubMed     Text format     Abstract available


  186. YANG R, Gui X, Xiong Y, Gao S, et al
    Long-term Follow-up of Patients Triply Infected with HIV and Hepatitis B and C Viruses in a Comprehensive Hospital in Central China.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12739.
    PubMed     Text format     Abstract available


  187. JOHNSON K, Green PK, Ioannou GN
    Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12731.
    PubMed     Text format     Abstract available


  188. EL SHERIF O, Afhdal N, Curry M
    No one size fits all - shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12734.
    PubMed     Text format     Abstract available


    May 2017
  189. FITCH DN, Dharod A, Campos CL, Nunez M, et al
    Use of Electronic Health Record Clinical Decision Support Tool for HCV Birth Cohort Screening.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12729.
    PubMed     Text format     Abstract available


  190. ROB B, Moreno C, Van Vlierberghe H, Bourgeois S, et al
    The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience.
    J Viral Hepat. 2017 May 15. doi: 10.1111/jvh.12726.
    PubMed     Text format     Abstract available


  191. OSIBOGUN O, Ogunmoroti O, Michos ED, Spatz ES, et al
    HIV/HCV Co-infection and the risk of Cardiovascular Disease: A Meta-analysis.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12725.
    PubMed     Text format     Abstract available


  192. MCLEOD A, Cullen BL, Hutchinson SJ, Roy KM, et al
    Limited Impact of Awareness-Raising Campaigns on Hepatitis C Testing Practices among General Practitioners.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12724.
    PubMed     Text format     Abstract available


  193. KIM GA, Han S, Kim HD, An J, et al
    Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.
    J Viral Hepat. 2017 May 12. doi: 10.1111/jvh.12723.
    PubMed     Text format     Abstract available


  194. WEDEMEYER H, Craxi A, Zuckerman E, Dieterich D, et al
    Real-World Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in Patients with HCV Genotype 1 or 4 Infection: a Meta-Analysis.
    J Viral Hepat. 2017 May 8. doi: 10.1111/jvh.12722.
    PubMed     Text format     Abstract available


  195. SHAWA IT, Felmlee DJ, Hegazy D, Sheridan DA, et al
    Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12720.
    PubMed     Text format     Abstract available


  196. HLAING NKT, Mitrani RA, Aung ST, Phyo WW, et al
    Safety and Efficacy of Sofosbuvir-Based DAA Regimens for Hepatitis C Virus Genotypes 1 - 4 and 6 in Myanmar: Real-world experience.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12721.
    PubMed     Text format     Abstract available


  197. GANE E, Nahass R, Luketic V, Asante-Appiah E, et al
    Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, non-cirrhotic HCV genotype 3-infected patients.
    J Viral Hepat. 2017 May 4. doi: 10.1111/jvh.12719.
    PubMed     Text format     Abstract available


    April 2017
  198. STEININGER K, Boyd A, Dupke S, Krznaric I, et al
    HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    J Viral Hepat. 2017 Apr 25. doi: 10.1111/jvh.12707.
    PubMed     Text format     Abstract available


  199. PAPASAVVAS E, Azzoni L, Yin X, Liu Q, et al
    HCV viremia associates with NK cell activation and dysfunction in anti retroviral HIV/HCV co-infected subjects.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12714.
    PubMed     Text format     Abstract available


  200. DE GROEN RA, Groothuismink ZMA, van Oord G, Kootstra NA, et al
    NK cells in self-limited HCV infection exhibit a more extensively differentiated, but not memory-like, repertoire.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12716.
    PubMed     Text format     Abstract available


    March 2017
  201. VUKOTIC R, Conti F, Fagiuoli S, Morelli MC, et al
    Long-term outcomes of DAAs in post-transplant advanced HCV recurrence and fibrosing cholestatic hepatitis.
    J Viral Hepat. 2017 Mar 28. doi: 10.1111/jvh.12712.
    PubMed     Text format     Abstract available


  202. BOGLIONE L, Mornese Pinna S, De Nicolo A, Cusato J, et al
    Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12711.
    PubMed     Text format     Abstract available


  203. WELZEL TM, Hinrichsen H, Sarrazin C, Buggisch P, et al
    Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12708.
    PubMed     Text format     Abstract available


  204. AFDHAL N, Everson GT, Calleja JL, McCaughan GW, et al
    Effect of Viral Suppression on Hepatic Venous Pressure Gradient in Hepatitis C With Cirrhosis and Portal Hypertension.
    J Viral Hepat. 2017 Mar 10. doi: 10.1111/jvh.12706.
    PubMed     Text format     Abstract available


  205. BUTI M, Dominguez-Hernandez R, Oyaguez I, Casado MA, et al
    Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12704.
    PubMed     Text format     Abstract available


  206. CHEW KW, Bhattacharya D, Horwich TB, Yan P, et al
    Performance of the Pooled Cohort Atherosclerotic Cardiovascular Disease Risk Score in Hepatitis C Virus-infected Persons.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12705.
    PubMed     Text format     Abstract available


  207. SHRIVASTAVA S, Wilson E, Poonia B, Tang L, et al
    Augmentation of HCV specific immunity and Sustained virological response (SVR).
    J Viral Hepat. 2017 Mar 7. doi: 10.1111/jvh.12702.
    PubMed     Text format     Abstract available


  208. CUNNINGHAM EB, Harjarizadeh B, Bretana NA, Amin J, et al
    Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study.
    J Viral Hepat. 2017 Mar 3. doi: 10.1111/jvh.12701.
    PubMed     Text format     Abstract available


  209. SMITH HL, Chung RT, Mantry P, Chapman W, et al
    Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
    J Viral Hepat. 2017;24:197-206.
    PubMed     Text format     Abstract available


  210. TAIT JM, Wang H, Stephens BP, Miller M, et al
    Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients.
    J Viral Hepat. 2017;24:207-215.
    PubMed     Text format     Abstract available


  211. AGUILERA A, Navarro D, Rodriguez Frias F, Viciana I, et al
    Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (The GEHEP 005 study).
    J Viral Hepat. 2017 Mar 1. doi: 10.1111/jvh.12700.
    PubMed     Text format     Abstract available


    February 2017
  212. SHAKER OG, Senousy MA
    Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12696.
    PubMed     Text format     Abstract available


  213. DASHTSEREN B, Bungert A, Bat-Ulzii P, Enkhbat M, et al
    Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey among Mongolian adults.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12697.
    PubMed     Text format     Abstract available


  214. GRANNAN S
    Understanding Patient Perceptions and Risk for Hepatitis C Screening.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12692.
    PubMed     Text format     Abstract available


  215. INGILIZ P
    Martinello et al.,HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2017 Feb 7. doi: 10.1111/jvh.12686.
    PubMed     Text format     Abstract available


  216. EL-AKEL W, El-Sayed MH, El Kassas M, El-Serafy M, et al
    National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.
    J Viral Hepat. 2017 Feb 1. doi: 10.1111/jvh.12668.
    PubMed     Text format     Abstract available


    January 2017
  217. JANJUA NZ, Islam N, Wong J, Yoshida EM, et al
    Shift in disparities in Hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12684.
    PubMed     Text format     Abstract available


  218. DIRKS M, Pflugrad H, Haag K, Tillmann HL, et al
    Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!
    J Viral Hepat. 2017 Jan 24. doi: 10.1111/jvh.12674.
    PubMed     Text format     Abstract available


  219. MENDIZABAL M, Reddy KR
    Chronic Hepatitis C and Chronic Kidney disease: Advances, Limitations and Unchartered Territories.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12681.
    PubMed     Text format     Abstract available


  220. FERNANDEZ-PONCE C, Munoz-Miranda JP, Arbulo-Echevarria MM, Litran R, et al
    Immune modulation by the Hepatitis C virus core protein.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12675.
    PubMed     Text format     Abstract available


  221. ZHOU S, Cella E, Zhou W, Kong WH, et al
    Population dynamics of HCV subtypes in injecting drug-users on methadone maintenance treatment in China associated with economic and health reform.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12677.
    PubMed     Text format     Abstract available


  222. VUKOTIC R, Di Donato R, Conti F, Scuteri A, et al
    Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.
    J Viral Hepat. 2017;24:13-16.
    PubMed     Text format     Abstract available


    December 2016
  223. GOEL A, Sanchez J, Paulino L, Feuille C, et al
    A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12669.
    PubMed     Text format     Abstract available


  224. AYOUB H, Abu-Raddad LJ
    Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12671.
    PubMed     Text format     Abstract available


  225. MARTINELLO M, Grebely J, Petoumenos K, Gane E, et al
    HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2016 Dec 27. doi: 10.1111/jvh.12666.
    PubMed     Text format     Abstract available


  226. TOYODA H, Tada T, Takaguchi K, Senoh T, et al
    Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepa
    J Viral Hepat. 2016 Dec 16. doi: 10.1111/jvh.12665.
    PubMed     Text format     Abstract available


  227. PERELLO C, Carrion JA, Ruiz-Antoran B, Crespo J, et al
    Effectiveness and safety of ombitasvir, paritaprevir, ritonavir +/- dasabuvir +/- ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12637.
    PubMed     Text format     Abstract available


  228. MUNOZ-GOMEZ R, Rincon D, Ahumada A, Hernandez E, et al
    Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotype 1 and 4 hepatitis C virus infection (HCV) in patients with severe renal impairment: a multicenter experience.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12664.
    PubMed     Text format     Abstract available


  229. CONTI F, Brillanti S, Buonfiglioli F, Vukotic R, et al
    Safety and efficacy of direct acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12663.
    PubMed     Text format     Abstract available


  230. ELBASHA E, Greaves W, Roth D, Nwankwo C, et al
    Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    J Viral Hepat. 2016 Dec 13. doi: 10.1111/jvh.12639.
    PubMed     Text format     Abstract available


  231. XIONG H, Rong X, Wang M, Xu R, et al
    HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China.
    J Viral Hepat. 2016 Dec 12. doi: 10.1111/jvh.12644.
    PubMed     Text format     Abstract available


  232. ALONSO S, Riveiro-Barciela M, Fernandez I, Rincon D, et al
    Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12648.
    PubMed     Text format     Abstract available


  233. ALQAHTANI S, Ozaras R, Isakov V, Wyles D, et al
    Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12641.
    PubMed     Text format     Abstract available


  234. SHAH SR, Chowdhury A, Mehta R, Kapoor D, et al
    Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12654.
    PubMed     Text format     Abstract available


  235. DING Y, Duan S, Ye R, Yang Y, et al
    More Improvement than Progression of Liver Fibrosis Following Antiretroviral Therapy in A Longitudinal Cohort of HIV-infected Patients With or Without HBV and HCV Co-infections.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12658.
    PubMed     Text format     Abstract available


  236. GIMENO-BALLESTER V, Buti M, San Miguel R, Riveiro M, et al
    Interferon-free therapies for Patients with Chronic Hepatitis C Genotype 3 Infection: A Systematic Review.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12660.
    PubMed     Text format     Abstract available


  237. GITTO S, Gamal N, Andreone P
    NS5A inhibitors for the treatment of hepatitis C infection.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12657.
    PubMed     Text format     Abstract available


  238. WARING JF, Davis JW, Dumas E, Cohen D, et al
    Epigenetic analysis of the IFNlambda3 gene identifies a novel marker for response to therapy in HCV-infected subjects.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12661.
    PubMed     Text format     Abstract available


  239. CHANG LY, Li Y, Kaplan DE
    Hepatitis C viremia reversibly maintains subset of antigen-specific T-bet+ tissue-like memory B-cells.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12659.
    PubMed     Text format     Abstract available


  240. ALAEI A, Alaei K, Waye K, Tracy M, et al
    Hepatitis C Infection and Other Drug Related Harms Among Inpatients Who Injected Drugs in Turkey.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12662.
    PubMed     Text format     Abstract available


  241. DURIER N, Yunihastuti E, Ruxrungtham K, Kinh NV, et al
    Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12630.
    PubMed     Text format     Abstract available


  242. KANAAN N, Raggi C, Goffin E, De Meyer M, et al
    Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12655.
    PubMed     Text format     Abstract available


  243. EMMANUEL B, Shardell MD, Tracy L, Kottilil S, et al
    Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12656.
    PubMed     Text format     Abstract available


  244. LLANERAS J, Riveiro-Barciela M, Buti M, Esteban R, et al
    Hepatitis C virus genotype 4: Genotype 1's little brother.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12620.
    PubMed     Text format     Abstract available


    November 2016
  245. ISLAM N, Krajden M, Gilbert M, Gustafson P, et al
    Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12650.
    PubMed     Text format     Abstract available


  246. MCDONALD SA, Innes HA, Aspinall E, Hayes PC, et al
    Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12646.
    PubMed     Text format     Abstract available


  247. BARTLETT SR, Wertheim JO, Bull RA, Matthews GV, et al
    A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.
    J Viral Hepat. 2016 Nov 24. doi: 10.1111/jvh.12652.
    PubMed     Text format     Abstract available


  248. LAWITZ E, Poordad F, Gutierrez JA, Kakuda TN, et al
    Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    J Viral Hepat. 2016 Nov 23. doi: 10.1111/jvh.12645.
    PubMed     Text format     Abstract available


  249. BRUNO G, Saracino A, Fabrizio C, Scudeller L, et al
    Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: A "turning-off" effect of liver inflammation?
    J Viral Hepat. 2016 Nov 14. doi: 10.1111/jvh.12636.
    PubMed     Text format    


  250. HEZODE C
    Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
    J Viral Hepat. 2016 Nov 9. doi: 10.1111/jvh.12635.
    PubMed     Text format     Abstract available


  251. KHARABIAN MASOULEH S, Herzig S, Klose L, Roggenhofer E, et al
    Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study.
    J Viral Hepat. 2016 Nov 4. doi: 10.1111/jvh.12634.
    PubMed     Text format     Abstract available


  252. RODRIGO C, Eltahla AA, Bull RA, Luciani F, et al
    Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12616.
    PubMed     Text format     Abstract available


  253. THOMPSON AJ, Bowden DS
    Vidal LL, et al. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct HCV genotypes from worldwide treatment-naive subjects. JVH, 2016, 23(11): 840-849.
    J Viral Hepat. 2016;23:838-839.
    PubMed     Text format    


    October 2016
  254. ESMAEILI A, Mirzazadeh A, Carter GM, Esmaeili A, et al
    Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.
    J Viral Hepat. 2016 Oct 28. doi: 10.1111/jvh.12628.
    PubMed     Text format     Abstract available


  255. EL RAZIKY M, Gamil M, Ashour MK, Sameea EA, et al
    Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naive and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
    J Viral Hepat. 2016 Oct 27. doi: 10.1111/jvh.12625.
    PubMed     Text format     Abstract available


  256. LAFFERTY L, Treloar C, Guthrie J, Chambers GM, et al
    Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.
    J Viral Hepat. 2016 Oct 24. doi: 10.1111/jvh.12627.
    PubMed     Text format     Abstract available


  257. TAPPER EB, Bacon BR, Curry MP, Dieterich DT, et al
    Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
    J Viral Hepat. 2016 Oct 11. doi: 10.1111/jvh.12611.
    PubMed     Text format     Abstract available


  258. CRISAN D, Radu C, Suciu A, Leach N, et al
    Hepatitis C in nonobese nondiabetic patients: Insulin resistance and the metabolic syndrome make a difference.
    J Viral Hepat. 2016 Oct 4. doi: 10.1111/jvh.12610.
    PubMed     Text format    


  259. FEVERY B, Verbinnen T, Peeters M, Janssen K, et al
    Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    J Viral Hepat. 2016 Oct 3. doi: 10.1111/jvh.12614.
    PubMed     Text format     Abstract available


    September 2016
  260. WONG RJ, Nguyen MT, Trinh HN, Huynh A, et al
    Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
    J Viral Hepat. 2016 Sep 27. doi: 10.1111/jvh.12609.
    PubMed     Text format     Abstract available


  261. EMMANUEL B, Sidique N, Zhang X, Poonia B, et al
    Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12618.
    PubMed     Text format     Abstract available


  262. ELTAHLA AA, Rodrigo C, Betz-Stablein B, Grebely J, et al
    Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12615.
    PubMed     Text format     Abstract available


    July 2016
  263. NISHIKAWA H, Enomoto H, Iwata Y, Kishino K, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.
    J Viral Hepat. 2016 Jul 31. doi: 10.1111/jvh.12575.
    PubMed     Text format     Abstract available


    December 2015
  264. ZHOU X, Xu L, Wang W, Watashi K, et al
    Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.
    J Viral Hepat. 2015 Dec 1. doi: 10.1111/jvh.12491.
    PubMed     Text format     Abstract available


    August 2015
  265. YOUNOSSI ZM, Stepanova M, Saab S, Ahmed A, et al
    The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.
    J Viral Hepat. 2015 Aug 20. doi: 10.1111/jvh.12449.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: